Morepen Laboratories
Morepen Laboratories Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Morepen Laboratories Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Morepen Laboratories Ltd trades at a P/E of 28.97× and P/B of 2.26×.
Valuation
Profitability
Growth
Financial Health
Morepen Laboratories Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Morepen Laboratories Ltd, switchable between annual and quarterly views, consolidated or standalone.
Morepen Laboratories Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,734.29 Cr and reported EPS of ₹1.73.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 607 | 769 | 853 | 1,188 | 1,547 | 1,418 | 1,690 | 1,812 | 1,806 |
| Other Income | 4 | 4 | 9 | 12 | 10 | 6 | 14 | 18 | 21 |
| Total Income | 610 | 772 | 863 | 1,200 | 1,557 | 1,424 | 1,704 | 1,830 | 1,827 |
| Cost of Goods Sold (COGS) | 369 | 496 | 557 | 781 | 1,049 | 956 | 1,062 | 1,159 | 1,123 |
| Gross Profit | 238 | 272 | 296 | 408 | 498 | 462 | 628 | 652 | 682 |
| +Operating Expenses | 173 | 205 | 227 | 289 | 361 | 382 | 469 | 478 | 557 |
| EBITDA | 65 | 68 | 69 | 119 | 137 | 80 | 159 | 174 | 126 |
| +Non-Operating Expenses | 39 | 42 | 39 | 32 | 20 | 30 | 37 | 37 | 79 |
| Profit Before Tax (PBT) | 30 | 29 | 39 | 99 | 127 | 56 | 135 | 155 | 120 |
| +Tax Expense | — | 0 | 6 | 1 | 25 | 17 | 39 | 37 | 24 |
| Profit After Tax (PAT) | 30 | 29 | 34 | 97 | 102 | 39 | 96 | 118 | 95 |
| Earnings Per Share (EPS) | 0.66 | 0.64 | 0.75 | 2.16 | 2.13 | 0.76 | 1.88 | 2.15 | 1.73 |
| Diluted Shares Outstanding (Nos.) | 45 | 45 | 45 | 45 | 48 | 51 | 51 | 55 | 55 |
| +Additional Disclosures | 949 | 1,238 | 1,378 | 1,882 | 2,479 | 2,322 | 2,629 | 2,834 | 2,862 |
| Sales Growth % | — | 26.72 | 11.00 | 39.27 | 30.20 | -8.36 | 19.25 | 7.17 | -0.32 |
| YoY Sales Growth % | — | 26.72 | 11.00 | 39.27 | 30.20 | -8.36 | 19.25 | 7.17 | -0.32 |
| Material Cost % | 36 | 45 | 48 | 52 | 52 | 55 | 52 | 55 | 58 |
| Employee Cost % | 13 | 12 | 13 | 11 | 11 | 11 | 11 | 12 | 13 |
| Other Cost % | 16 | 14 | 14 | 13 | 13 | 16 | 17 | 15 | 18 |
| OPM % | 11 | 9 | 8 | 10 | 9 | 6 | 9 | 10 | 7 |
| Tax % | — | 1 | 14 | 1 | 20 | 31 | 29 | 24 | 20 |
| Profit Growth % | — | -2.51 | 16.40 | 189.13 | 4.73 | -61.96 | 148.63 | 22.73 | -19.61 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 30 | 28 | 32 | 88 | 109 | 52 | 125 | 145 | 89 |
Morepen Laboratories segment analysis: revenue and profit mix.
Disclosed business segments at Morepen Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Morepen Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Morepen Laboratories Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Morepen Laboratories Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Morepen Laboratories Ltd's investment case rests on 6 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
Morepen Laboratories demonstrates strong operational efficiency with a healthy Return on Equity (ROE) of 11.80% and Return on Capital Employed (ROCE) of 15.10%, indicating effective utilization of capital and shareholder investments for profit generation.
The company maintains a very low debt-to-equity ratio of 0.09, signifying a robust financial structure and minimal reliance on borrowed capital, which enhances its financial stability and reduces risk for investors.
With a Price-to-Earnings (PE) ratio of 28.90, which is comparable to the sector PE of 27.77, the company appears reasonably valued. A positive dividend yield of 0.41% also offers an additional return for investors.
Operating in the "Pharmaceuticals" and "Healthcare" sectors, Morepen Laboratories stands to benefit from the inherent growth drivers of these industries, including increasing healthcare spending and demand for new drugs.
Despite current challenges, the company's PE ratio of 28.90 is lower than some peers (e.g., Divi's Lab at 74.95), suggesting potential for a valuation re-rating if it can demonstrate sustained profit and sales recovery.
What can break it.
Morepen Laboratories experienced a substantial quarterly profit decline of -70.30%, indicating significant operational challenges or market headwinds that could impact short-term earnings stability and investor confidence.
The company's quarterly sales growth shows a negative trend of -6.59%, suggesting a potential slowdown in market demand or increased competitive pressures, which warrants further investigation into its revenue generation.
The current stock price of 48.80 is significantly below its 52-week high of 91.70, representing a substantial decline. This indicates considerable price volatility and potential investor concerns.
Promoter holding has decreased from 38.22% to 35.66% recently, potentially signaling a dilution of stake. A high public shareholding of 61.22% could also contribute to stock volatility.
Morepen Laboratories faces significant competition from larger, more established peers like Sun Pharma and Dr Reddy's, which boast higher ROCE and market share, potentially limiting its growth and pricing power.
What would change my mind.
Trim if P/E re-rates above 38. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 17.17. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Morepen Laboratories Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Morepen Laboratories Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Morepen Laboratories Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Morepen Laboratories Ltd — derived from the live tape, not yesterday's close.
Morepen Laboratories Ltd last traded at ₹50.12 with an intraday range of ₹48.21–₹51.49 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹50.12| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 58.23 | +8.11 | +16.18% |
| R3 | 54.95 | +4.83 | +9.64% |
| R2 | 53.22 | +3.10 | +6.19% |
| R1 | 51.67 | +1.55 | +3.09% |
| PIVOT | 49.94 | -0.18 | -0.36% |
| CURRENT | 50.12 | — | — |
| S1 | 41.83 | -8.29 | -16.54% |
| S2 | 45.11 | -5.01 | -10.00% |
| S3 | 46.66 | -3.46 | -6.90% |
| S4 | 48.39 | -1.73 | -3.45% |
MOREPENLAB is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: 48.21 ~ 48.8
Trading Above opening range, showing Bullishness
Morepen Laboratories Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Morepen Laboratories Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Morepen Laboratories Ltd stood at 29.0% of traded volume, against a 20-day average of 33.1%.
Morepen Laboratories announcements: results, concalls, ratings, M&A.
Filings Morepen Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Morepen Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 64 documents below.
Copy of Newspaper Publication
Morepen Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Investor Presentation
Morepen Laboratories Limited has informed the Exchange about Investor Presentation
Press Release
Morepen Laboratories Limited has informed the Exchange regarding a press release dated May 27, 2026, titled "Morepen Labs Q4 Net Profit Rises 69%;…
Agreements
Morepen Laboratories Limited has informed the Exchange about execution of loan agreement with Shinhan Bank
Press Release
Morepen Laboratories Limited has informed the Exchange regarding a press release dated April 17, 2026, titled "Morepen Secures Fourth Consecutive…
Investor decks & rating reports.
Morepen Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Morepen Laboratories has declared, sequenced by announce and record date.
Morepen Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Morepen Laboratories Ltd: business, sector, key facts.
What Morepen Laboratories Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Morepen Laboratories Ltd operates in the Healthcare, listed as NSE: MOREPENLAB, BSE: 500288.
Morepen Laboratories Limited is a multinational company headquartered in Gurugram, India, established in 1984. Their core business revolves around the development, manufacturing, marketing, and sale of a diverse range of healthcare products across several key sectors. This includes a significant presence in the Active Pharmaceutical Ingredients (API) market, providing crucial components for various medications.
A substantial portion of Morepen's business focuses on the production and distribution of APIs. These APIs are used in the creation of pharmaceuticals targeting a wide spectrum of conditions, including allergies (anti-histaminic, anti-asthmatic), cardiovascular issues (anti-lipemic, anti-hypertensive, anti-coagulant), diabetes (anti-diabetic), ulcers (anti-ulcerative), and mental health (anti-depressant). This underscores their significant role in the pharmaceutical supply chain.
Beyond APIs, Morepen Laboratories also manufactures and sells a broad range of home healthcare products. This segment encompasses a considerable selection of diagnostic tools and equipment, such as blood glucose monitors and test strips, blood pressure monitors (sphygmomanometers), digital thermometers, nebulizers, pulse oximeters, and even air purifiers. This comprehensive array of products caters to both professional and personal healthcare needs.
Furthermore, Morepen offers a diverse portfolio of Over-The-Counter (OTC) and healthcare products marketed under the prominent "Dr. Morepen" brand. This includes a wide array of medications and remedies designed to address common ailments like fever, pain, constipation, and acidity. The brand also extends to products focused on specific health areas, encompassing formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, allergy treatment, central nervous system disorders, cardiology, diabetology, and nutraceuticals. This demonstrates a strategic approach to capturing a broad market share across various healthcare segments.
In summary, Morepen Laboratories' business model is multifaceted and encompasses a vertically integrated approach from the production of APIs to the development and marketing of finished pharmaceutical products and home healthcare devices. Their geographical reach extends internationally, with a focus on India and the United States, demonstrating a considerable level of market penetration and a robust business strategy.
Questions investors ask about Morepen Laboratories Ltd (MOREPENLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Morepen Laboratories Ltd (MOREPENLAB)?
The current share price of Morepen Laboratories Ltd (MOREPENLAB) is ₹50.12. Today, the stock has gained by ₹2.83 (5.98%), trading in a range of ₹48.21 to ₹51.49. The stock opened at ₹48.26 with a trading volume of 1,82,07,733 shares.
02Is Morepen Laboratories Ltd stock a good investment for long-term?
Morepen Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,734.29 crores, P/E ratio of 28.97, ROE of 7.86%, and ROCE of 15.10%. The dividend yield stands at 0.42%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Morepen Laboratories Ltd stock?
The 52-week high price of Morepen Laboratories Ltd (MOREPENLAB) is ₹0, while the 52-week low is ₹0. Currently trading at ₹50.12, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Morepen Laboratories Ltd stock at the current price?
Whether to buy Morepen Laboratories Ltd stock at ₹50.12 depends on multiple factors. The stock is currently trading with a P/E ratio of 28.97 and P/B ratio of 2.26. Today's performance shows a gain of 5.98%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Morepen Laboratories Ltd and when is the next dividend?
Morepen Laboratories Ltd offers a dividend yield of 0.42%, which means for every ₹100 invested at the current price of ₹50.12, you can expect to receive approximately ₹0.42 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Morepen Laboratories Ltd?
Morepen Laboratories Ltd's key financial metrics include: P/E Ratio: 28.97, P/B Ratio: 2.26, ROE: 7.86%, ROCE: 15.10%, Dividend Yield: 0.42%, EPS: ₹1.73, Book Value: ₹22.17, and Debt-to-Equity: 16.67. The company's market cap stands at ₹2,734.29 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Morepen Laboratories Ltd stock performing today in the market?
Morepen Laboratories Ltd stock opened at ₹48.26 and is currently trading at ₹50.12, showing a gain of ₹2.83 (5.98%). The intraday high is ₹51.49 and low is ₹48.21. The trading volume stands at 1,82,07,733 shares, indicating strong market participation today.
08What is the P/E ratio of Morepen Laboratories Ltd and what does it indicate?
Morepen Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 28.97, which means investors are willing to pay ₹28.97 for every ₹1 of earnings. With an EPS of ₹1.73, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Morepen Laboratories Ltd (MOREPENLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy